Talquetamab for hard-to-treat myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests an investigational drug, talquetamab, for people with generalized myasthenia gravis that hasn't responded well to standard treatments. If you have active symptoms despite current therapy, this trial may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have generalized myasthenia gravis (weakness in arms, legs, or other body muscles, not just eyes) that is confirmed by your doctor and a positive antibody test against acetylcholine receptors.
- Your disease is considered 'refractory' meaning standard treatments haven't worked well enough, or you can't take them due to side effects.
- You have at least moderate daily symptoms affecting activities like walking, talking, or swallowing (MG-ADL score of 6 or higher, mostly from non-eye symptoms).
- You have been on a stable dose of Mestinon (pyridostigmine) for at least 1 week before starting.
- You haven't changed your steroid dose or received certain therapies (like IVIG or plasma exchange) in the last 4 weeks, and no B-cell depleting drugs or immunosuppressant dose changes in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, ripertamab, for people with generalized myasthenia gravis (gMG). It aims to see if targeting certain immune cells can help reduce symptoms like muscle weakness.
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
This trial tests a new drug called blinatumomab for people with refractory myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if the drug can help control muscle weakness and improve quality of life.
Hear when a new Myasthenia Gravis (MG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.